Last reviewed · How we verify
Placebo to telcagepant tablets
Telcagepant is a calcitonin gene-related peptide receptor antagonist.
Telcagepant is a calcitonin gene-related peptide receptor antagonist. Used for Acute treatment of migraine attacks with or without aura.
At a glance
| Generic name | Placebo to telcagepant tablets |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | CGRP receptor antagonist |
| Target | CGRP receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
It works by blocking the action of calcitonin gene-related peptide (CGRP), a molecule involved in the transmission of pain signals. This leads to a reduction in migraine frequency and severity. By inhibiting CGRP, telcagepant helps to alleviate migraine symptoms.
Approved indications
- Acute treatment of migraine attacks with or without aura
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
Key clinical trials
- Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065) (PHASE2, PHASE3)
- A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046) (PHASE2)
- Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034) (PHASE3)
- A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014) (PHASE1)
- Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) (PHASE3)
- MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) (PHASE2)
- Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) (PHASE3)
- Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to telcagepant tablets CI brief — competitive landscape report
- Placebo to telcagepant tablets updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI